PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatocellular carcinoma |
| Phenotype | C0035078|renal failure |
| Sentences | 5 |
| PubMedID- 24459641 | Exclusion criteria were an age younger than 19 or older than 75 years, shock status requiring a vasopressor, active infection (e.g., spontaneous bacterial peritonitis), acute renal failure of any cause, hepatocellular carcinoma or a history of another primary malignancy within 3 years, clinically relevant coronary artery disease (nyha functional angina classification iii/iv), congestive heart failure nyha iii/iv, clinically relevant cardiomyopathy, history of myocardial infarction in the past 1 year, poorly controlled hypertension (blood pressure >150/100) mmhg, transaminases above tenfold the upper limit of normal, ongoing antiviral therapy, the use of vasoactive drugs, including beta-blockers, diuretics, and anti-inflammatory drugs, pregnancy or lactation, involvement in another study within 90 days, and medical or psychological conditions that would not permit the subject to complete the study or sign informed consent. |
| PubMedID- 24325340 | Patients who had at admission renal failure, other causes of hemolytic anemia, hepatocellular carcinoma, sepsis, and/or active bleeding, were excluded. |
| PubMedID- 19818004 | renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization. |
| PubMedID- 24910704 | Patients with renal failure, history of hepatocellular carcinoma and cholangiocarcinoma, hypersensitivity to g-csf and patients receiving immunosuppressive medications like tacrolimus, cyclosporine, azathioprine and sirolimus were also excluded. |
| PubMedID- 23639221 | Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: a pharmacokinetic study. |
Page: 1